The association between uric acid levels and cardiorenal outcomes and death in patients with type 2 diabetes: a SUB-analysis of empa-REG outcome
Abstract
Plasma uric acid (UA) has been proposed as a biomarker of cardiovascular (CV) risk, but data are limited. UA levels may also modulate the effectiveness of CV risk reduction therapies.
In EMPA-REG OUTCOME, patients (N=7020) with type 2 diabetes (T2D) and CV disease were treated with empagliflozin 10
Read the paper
Related studies
- Risk Factors for Coronavirus Disease 2019 (COVID-19) Death in a Population Cohort Study from the Western Cape Province, South Africa
- Global and regional estimates of genital human papillomavirus prevalence among men: a systematic review and meta-analysis
- A methodology for assessing deployment trauma and its consequences in OEF/OIF/OND veterans: The TRACTS longitudinal prospective cohort study
- Post‑COVID‑19 Syndrome in Outpatients: a Cohort Study
- Factors Influencing Primary and Secondary Implant Stability—A Retrospective Cohort Study with 582 Implants in 272 Patients
- Electroacupuncture for Painful Diabetic Peripheral Neuropathy: A Multicenter, Randomized, Assessor-Blinded, Controlled Trial
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.